Evidence map›Paper›PMID 34453829›Full record

ArticleEuropean heart journal. Acute cardiovascular care2021

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases.

Sofie A Gevaert, Sigrun Halvorsen, Peter R Sinnaeve, Antonia Sambola, Geeta Gulati, Patrizio Lancellotti, Peter Van Der Meer, Alexander R Lyon, Dimitrios Farmakis, Geraldine Lee and 4 more

Registry-linked trialOpen access · bronzeAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in European heart journal. Acute cardiovascular care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05976893 (Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05976893 phase4unknown statusstarted 2023, after this paper: background citation

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Ran2023Enrolled620Registered outcomes5Posted comparisons0ConditionsASCVD, Atherosclerotic Cardiovascular Disease, Cancer, Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorArmsEvolocumab, Statin
PMID 30403574PMID 25773607PMID 28304224PMID 26039521PMID 36031810PMID 35508320PMID 29653628PMID 24161333PMID 21543628PMID 32370478PMID 35736631PMID 35760720other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Review
  4. Five-year retrospective analysis of invasiveCardiovascular diagnosis and therapy · 2026
    Article
  5. Review
  6. Immune checkpoint inhibitors and myocardial infarction.Journal of thrombosis and thrombolysis · 2026
    Review
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Cardio-oncology: chances and challenges.Basic research in cardiology · 2025
    Review
  16. Short- and long-term outcomes of patients with active cancer presenting with an acute coronary syndrome.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Exploring Frailty in the Intersection of Cardiovascular Disease and Cancer in Older People.International journal of environmental research and public health · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 7 countries.

Sofie A GevaertDepartment of Cardiology, Ghent University Hospital, C Heymanslaan 10, 9000 Gent, Belgium.ORCID 0000-0002-8721-3003
Sigrun HalvorsenDepartment of Cardiology, Oslo University Hospital Ulleval and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
Peter R SinnaeveDepartment of Cardiology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium.
Antonia SambolaDepartment of Cardiology, University Hospital Vall d'Hebron, Universitat Autonòma, CIBER-CV, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.
Geeta GulatiDepartment of Cardiology, Oslo University Hospital Ulleval and University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
Patrizio LancellottiUniversity of Liège Hospital, GIGA Cardiovascular Science and Department of Cardiology, CHU Sart Tilman, Avenue del'Hôpital 1, 4000 Liège, Belgium.ORCID 0000-0002-0804-8194
Peter Van Der MeerDepartment of Cardiology, University of Groningen University Medical Center Groningen and University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Alexander R LyonCardio-Oncology Clinic at Royal Brompton Hospital and Imperial College, Sydney street, SW3 6NP London, UK.
Dimitrios FarmakisUniversity of Cyprus Medical School, Agio Nikolaou street 93, 2408 Nicosia, Cyprus.
Geraldine LeeFlorence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College, Strand, WC2R 2LS London, UK.
Giuseppe BorianiCardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia and Policlinico Di Modena, Via Giuseppe Campi 287, 41125 Modena, Italy.ORCID 0000-0002-9820-4815
Ashutosh WechalekarDepartment of Haematology, University College London/University College London Hospitals, Huntley street 72, WC1E 6DD London, UK.
Alicia OkinesDepartment of Medicine, The Royal Marsden NHS Foundation Trust, Fulham road 203, SW3 6JJ London, UK.
Riccardo AsteggianoInsubria University, Via Ravasi 2, 21100 Varese, Italy.ORCID 0000-0002-2273-7228
Oslo University Hospital · NOCentro de Investigación en Red en Enfermedades Cardiovasculares · ESFlorence Nightingale Foundation · GBGhent University Hospital · BEKU Leuven · BERoyal Brompton Hospital · GBRoyal Marsden NHS Foundation Trust · GBUniversity Medical Center Groningen · NLUniversity of Cyprus · CYUniversity of Insubria · ITUniversity of Liège · BEUniversity of London · GBUniversity of Modena and Reggio Emilia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to the cancer itself or the cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. We summarize the most common acute CV complications of cytotoxic, targeted, and immune-based therapies. This is followed by a proposal for a multidisciplinary approach where acute cardiologists work close together with the treating oncologists, haematologists, and radiation specialists, especially in situations where immediate therapeutic decisions are needed. In this first part, we further focus on the management of acute coronary syndromes and acute pericardial diseases in patients with cancer.

Indexed as

Acute Coronary SyndromeCardiovascular DiseasesNeoplasmsHumansPericardiumAcute coronary syndromesCancer therapyCardio-oncologyPericardial effusionPericarditisTamponade

Identifiers

PMID34453829
OpenAlexW3198376841

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.